The New England journal of medicine

• Latest
• Best
• Search…

• N. Engl. J. Med. · Aug 2017

  Multicenter Study Clinical Trial

  Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.

  Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran. ⋯ In emergency situations, idarucizumab rapidly, durably, and safely reversed the anticoagulant effect of dabigatran. (Funded by Boehringer Ingelheim; RE-VERSE AD ClinicalTrials.gov number, NCT02104947 .).

  expand abstract… mark as read…

• N. Engl. J. Med. · Aug 2017

  Review

  Evidence for Health Decision Making - Beyond Randomized, Controlled Trials.

  no abstract available

  explore further… or just mark as read…

• N. Engl. J. Med. · Aug 2017

  Case Reports

  Xanthomas in Familial Hypercholesterolemia.

  no abstract available

  expand abstract… mark as read…

• N. Engl. J. Med. · Aug 2017

  Case Reports

  All That Wheezes….

  no abstract available

  read on… or just mark as read…

• N. Engl. J. Med. · Aug 2017

  Cyberattack on Britain's National Health Service - A Wake-up Call for Modern Medicine.

  no abstract available

  keep going… mark as read…